Announcements Trials
Browse Landscape

Phase

Phase 1 6Phase 1/2 1

Status

Completed 5Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 4OTHER 3

Study Type

Interventional 7

Sponsor

Conditions

Breast Neoplasms 576Carcinoma, Non-Small-Cell Lung 490Ovarian Neoplasms 328Lung Neoplasms 208Fallopian Tube Neoplasms 153Neoplasms 152Stomach Neoplasms 128Esophageal Neoplasms 127Triple Negative Breast Neoplasms 125Neoplasm Metastasis 120Carcinoma, Ovarian Epithelial 115Squamous Cell Carcinoma of Head and Neck 96Endometrial Neoplasms 95Uterine Cervical Neoplasms 80Head and Neck Neoplasms 78Esophageal Squamous Cell Carcinoma 76Adenocarcinoma of Lung 49Recurrence 48Parkinson Disease 4, Autosomal Dominant Lewy Body 45Melanoma 42Carcinoma 42Urinary Bladder Neoplasms 41Adenocarcinoma Of Esophagus 36Small Cell Lung Carcinoma 34Carcinoma, Squamous Cell 34Prostatic Neoplasms 32Pancreatic Neoplasms 30Breast Neoplasms, Male 28Unspecified Adult Solid Tumor, Protocol Specific 27Adenocarcinoma, Bronchiolo-Alveolar 26

Interventions

Nivolumab 20Ipilimumab 10Surveys and Questionnaires 7Paclitaxel 7linrodostat 6Standard of Care 6Sirolimus 5Gemcitabine 5Bevacizumab 5temsirolimus 4relatlimab 4Pemetrexed 4Interviews as Topic 4Docetaxel 4Carboplatin 4ARRY-334543 4Vorinostat 3Erlotinib Hydrochloride 3Dasatinib 3Cetuximab 3regorafenib 2olaparib 2apatinib 2anlotinib 2abemaciclib 2Trastuzumab 2Sunitinib 2Sorafenib 2Olanzapine 2N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

7 trials
RecentStart dateEnrollment
Advanced Cancer × Paclitaxel × Clear all
NCT04495296 2025-12-19

A Trial to Evaluate Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of TST001 in Advanced or Metastatic Solid Tumors

Suzhou Transcenta Therapeutics Co., Ltd.

Phase 1/2 Recruiting
320 enrolled

Advanced Cancer

NCT02193633 2024-09-26

TAX-TORC

Royal Marsden NHS Foundation Trust

Phase 1 Completed
90 enrolled

Advanced Cancer

NCT05298592 2024-09-26

A Study of BMS-986406 as Monotherapy and Combination Therapies in Participants With Advanced Tumors

Bristol-Myers Squibb

Phase 1 Completed
77 enrolled

Advanced Cancer

NCT01113476 2022-09-02

Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

M.D. Anderson Cancer Center

Phase 1 Completed
176 enrolled

Advanced Cancer

NCT02383212 2020-01-27

Study of REGN2810 (Anti-PD-1) in Patients With Advanced Malignancies

Regeneron Pharmaceuticals

Phase 1 Completed
398 enrolled

Advanced Cancer

NCT01688791 2015-02-10

A Study of MK-8109 (Vintafolide) Given Alone or With Chemotherapy in Participants With Advanced Cancers (MK-8109-001)

Endocyte

Phase 1 Terminated
37 enrolled

Advanced Cancer

NCT00508326 2012-07-30

Paclitaxel Administered by HAI to Patients With Advanced Cancer and Dominant Liver Involvement

M.D. Anderson Cancer Center

Phase 1 Completed
27 enrolled

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡